Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.15 – $0.53
26% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $6.0K | $5.0K | $0 | $0 | $102.0K | $186.0K | $21.0K |
| Cost of revenue | $0 | $0 | $0 | $1.5M | $1.4M | $69.0K | $12.0K | −$1.9M |
| Gross profit | $3.1M | $6.0K | $5.0K | −$1.5M | −$1.4M | $33.0K | $174.0K | $1.9M |
| Gross margin | 100.0% | 100.0% | 100.0% | — | — | 32.4% | 93.5% | 9195.7% |
| R&D | $23.6M | $25.2M | $21.6M | $20.8M | $18.9M | $4.7M | $3.3M | $3.3M |
| Operating income | −$38.2M | −$28.9M | −$17.0M | −$26.4M | −$40.9M | −$8.5M | −$5.9M | −$7.2M |
| EBITDA | −$36.3M | −$26.5M | −$14.9M | −$25.4M | −$39.7M | −$7.8M | −$5.7M | −$7.0M |
| Net income | −$37.4M | −$28.6M | −$17.5M | −$26.5M | −$40.9M | −$8.4M | −$5.8M | $829.7K |
| Net margin | -1201.5% | -477200.0% | -350020.0% | — | — | -8282.4% | -3131.2% | 3952.6% |
| EPS (diluted) | -3.26 | -2.29 | -1.26 | -1.70 | -1.81 | -0.33 | -0.14 | 0.02 |
Annual figures · source: Financial Modeling Prep
CELYAD SA
No one on the platform currently holds CLYYF.
No tracked institution reports a position in CLYYF as of their last filing.
No one on the platform has traded CLYYF yet.
| $627628 |
| — |
| CLAZFClaritas Pharmaceuticals, Inc. | $0.00 | +0.00% | $3659 | — |
| ERYPERYTECH Pharma S.A. | $0.78 | +1.30% | $47M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 46.8× sales vs its 139.6× historical median P/S.
Fair value ≈ $0.75 · price $0.25 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.